USA 2014.

Trial name or title	Chronic Hypertension and Pregnancy (CHAP) Project (CHAP). ClinicalTrials.gov Identifier: NCT02299414
Methods	Pragmatic multicentre, open‐label RCT.
Participants	Target: 4700 women. Women with chronic hypertension in pregnancy with new or untreated chronic hypertension, blood pressure 140‐159 SBP or 90‐104 DBP OR known chronic hypertension on monotherapy and taking any antihypertensive and blood pressure ≤ 159/104 (including those with BP < 140/90); singleton; and viable pregnancy < 23 weeks of gestation.
Interventions	Treatment arm: 1st line anti‐hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or labetalol). Control arm: no anti‐hypertensive therapy (unless BP is severe).
Outcomes	Primary outcomes: composite adverse perinatal outcome (total reported fetal or neonatal death up to 2 weeks; pre‐eclampsia with severe features hypertension and proteinuria or hypertension and severe features per ACOG, placental abruption, or indicated PTB < 35 weeks not due to spontaneous preterm labour or membrane rupture).SGA (birthweight less than 10th percentile for gestational age at birth according to accepted national standard). Secondary outcomes: maternal death, heart failure, stroke, encephalopathy, myocardial infarction or ischaemia, pulmonary oedema, admission to neonatal or intensive care nursery, or renal failure; perinatal death, IVH III or IV, BPD or chronic lung disease, NEC, ROP, seizures, proven sepsis; adherence to antihypertensive therapy after delivery.
Starting date	09/2016.
Contact information	University of Alabama at Birmingham ‐ USA Clinical Coordinating Center Contact: Alan Tita, MD, PhD (205‐934‐5612) atita@uabmc.edu Contact: Michelle Feese, MPH (205‐975‐8633) mfeese@uab.edu
Notes	Ongoing.